Abstract
No public abstract is available from the verified source records.
Koohyar Ahmadzadeh, Zahra Heidari Meybodi, Gregory Y.H. Lip
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Real-world data: towards achieving the achievable in cancer care
10.1038/s41571-019-0167-7 · 2019
Real-world evidence: better than nothing or the future? A perspective on clinical evidence generation in interventional oncology
10.1007/s00270-025-04179-4 · 2026
Comparative effectiveness research using randomized trials and observational studies: validity and feasibility considerations
10.1055/a-2664-7887 · 2026
Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE registry-2
10.1055/a-2316-5269 · 2024
Risk of major bleeding with antiplatelet and/or anticoagulation therapy in inherited factor XI deficiency: insights from real-world observations
10.1055/a-2347-4338 · 2025
Impact of atrial fibrillation on thrombotic complications in myeloproliferative neoplasms real-world analysis
2026
Cardiovascular safety in oncology clinical trials: JACC: cardiooncology primer
10.1016/j.jaccao.2024.09.014 · 2025
Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports
2022
Oncologic benefits and cardiovascular risks of pembrolizumab: insights from a nationwide lung adenocarcinoma cohort
10.1016/j.jacasi.2026.07.019 · 2026
Generalisability of common oncology clinical trial eligibility criteria in the real world
10.1016/j.clon.2019.05.003 · 2019
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study
10.1016/s1470-2045(18)30608-9 · 2018
Differential cardiotoxicity of ibrutinib versus chemoimmunotherapy in chronic lymphocytic leukemia: a population-based study
10.3390/jcm13237492 · 2024
Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis
10.1080/10428194.2026.2653123 · 2026
Immortal time bias in national cancer database studies
10.1016/j.ijrobp.2019.07.056 · 2020
The timing, the treatment, the question: Comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example
10.1158/1055-9965.epi-22-0495 · 2022
Maximizing the impact of real-world evidence on cancer treatment: what do we need to achieve it?
10.57264/cer-2025-0186 · 2026
Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators
10.1002/pds.5407 · 2022
Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
10.2217/cer-2020-0013 · 2020
Competing risks data in clinical oncology
2024
Target trial emulation for regulatory and clinical decision making in cancer
10.1200/jco-25-01906 · 2026
No additional external references are available.